• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediciNova, Inc. - Common Stock (NQ:MNOV)

1.780 +0.150 (+9.20%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 274,503
Open 1.670
Bid (Size) 1.810 (100)
Ask (Size) 2.000 (100)
Prev. Close 1.630
Today's Range 1.670 - 1.840
52wk Range 1.168 - 3.900
Shares Outstanding 49,046,246
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Let's take a look at the stocks that are in motion in today's session. ↗
September 28, 2026
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
September 28, 2026
Via Chartmill

Performance

52-Week Range 54.4% below 52-week high
1.780
1.1752W Low 3.9052W High
1 Week 33.8% below 1-week high
1.631W Low 2.691W High

MediciNova, Inc. - Common Stock (MNOV) traded between $1.17 and $3.90 over the past 52 weeks and last traded at $1.78, 54.4% below its 52-week high. Over the past week it ranged between $1.63 and $2.69.

Past 12 Months
-31.0%
+23.6%
+24.5%
+23.6%
+33.8%
+42.4%
1W -$0.80
1M +$0.34
3M +$0.35
6M +$0.34
YTD +$0.45
1Y +$0.53

MNOV was +42.4% over the past year, +23.6% over six months, +33.8% year to date, -31.0% in the last week.

12 Months vs Market
MNOV
+42.4%
DIA
+10.1%
SPY
+15.1%
QQQ
+24.3%
IWM
+16.1%

Over the past 12 months MNOV returned +42.4% versus DIA (Dow) +10.1%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +16.1%.

Volume & Liquidity 0.88× 3-mo avg
Today 274,503 3-mo avg 312.4K
1W
563.6K
1M
812.9K
3M
312.4K
6M
180.0K
YTD
145.4K
1Y
339.9K

MNOV most recently traded 274,503 shares against a 3-month average daily volume of 312.4K.

More News

Read More
News headline image
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
September 28, 2026
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
September 24, 2026
From MediciNova, Inc.
Via GlobeNewswire
Unusual volume stocks in Tuesday's session ↗
September 22, 2026
Via Chartmill
Unusual volume stocks in Monday's session ↗
September 21, 2026
Via Chartmill
Unusual volume stocks in Friday's session ↗
September 18, 2026
Via Chartmill
News headline image
MediciNova to Participate in Two Investor Conferences in September
September 08, 2026
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
July 15, 2026
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova CEO Provides Shareholder Update
June 30, 2026
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
June 08, 2026
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
May 26, 2026
From MediciNova, Inc.
Via GlobeNewswire
News headline image
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
April 27, 2026
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova to Participate at the 38th Annual ROTH Conference
March 16, 2026
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
January 29, 2026
From MediciNova, Inc.
Via GlobeNewswire
News headline image
2026 New Year’s Greetings from the CEO
January 06, 2026
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
December 18, 2025
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
December 08, 2025
From MediciNova, Inc.
Via GlobeNewswire
News headline image
Message from the CEO to MediciNova Shareholders
December 01, 2025
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
November 18, 2025
From MediciNova, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
November 07, 2025
Via Benzinga
News headline image
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
November 06, 2025
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
November 04, 2025
From MediciNova, Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks in Monday's session ↗
November 03, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
October 31, 2025
Via Benzinga

Frequently Asked Questions

Is MediciNova, Inc. - Common Stock publicly traded?
Yes, MediciNova, Inc. - Common Stock is publicly traded.
What exchange does MediciNova, Inc. - Common Stock trade on?
MediciNova, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MediciNova, Inc. - Common Stock?
The ticker symbol for MediciNova, Inc. - Common Stock is MNOV on the Nasdaq Stock Market
What is the current price of MediciNova, Inc. - Common Stock?
The current price of MediciNova, Inc. - Common Stock is 1.780
When was MediciNova, Inc. - Common Stock last traded?
The last trade of MediciNova, Inc. - Common Stock was at 10/02/26 04:00 PM ET
What is the market capitalization of MediciNova, Inc. - Common Stock?
The market capitalization of MediciNova, Inc. - Common Stock is 87.30M
How many shares of MediciNova, Inc. - Common Stock are outstanding?
MediciNova, Inc. - Common Stock has 87M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap